168 related articles for article (PubMed ID: 38292814)
1. Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson's Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better?
Wu HF; Yu ELM; Sheng B; Wong KK; Au Yeung M; Wong WT; Kwan HH; Ng LP; Cheung CH; Lam YL; Chan YK
Clin Park Relat Disord; 2024; 10():100235. PubMed ID: 38292814
[TBL] [Abstract][Full Text] [Related]
2. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
[TBL] [Abstract][Full Text] [Related]
3. Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors.
Contin M; Lopane G; Marini L; Mohamed S; Sambati L; De Massis P; Guarino M; Sermi S; Persichella C; Cortelli P; Calandra-Buonaura G
Neurol Sci; 2023 Feb; 44(2):565-572. PubMed ID: 36350455
[TBL] [Abstract][Full Text] [Related]
4. Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients.
Phu AL; Xu Z; Brakoulias V; Mahant N; Fung VS; Moore GD; Martin A; Starcevic V; Krause M
J Clin Neurosci; 2014 Jan; 21(1):63-6. PubMed ID: 24035421
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
Seeman P
Synapse; 2015 Apr; 69(4):183-9. PubMed ID: 25645960
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky J; Pagonabarraga J
Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
[TBL] [Abstract][Full Text] [Related]
7. Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.
Staubo SC; Fuskevåg OM; Toft M; Lie IH; Alvik KMJ; Jostad P; Tingvoll SH; Lilleng H; Rosqvist K; Størset E; Odin P; Dietrichs E; Dietrichs ES
Eur J Neurol; 2024 Feb; 31(2):e16144. PubMed ID: 37955562
[TBL] [Abstract][Full Text] [Related]
8. Impulse control disorders in Parkinson's disease: a retrospective analysis of 1824 patients in a 12-year period.
Gunduz A; Çiftçi T; Erbil AC; Senoglu G; Ser MH; Apaydın H
Neurol Sci; 2024 Jan; 45(1):171-175. PubMed ID: 37581771
[TBL] [Abstract][Full Text] [Related]
9. A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists.
Rizos A; Sauerbier A; Antonini A; Weintraub D; Martinez-Martin P; Kessel B; Henriksen T; Falup-Pecurariu C; Silverdale M; Durner G; Røkenes Karlsen K; Grilo M; Odin P; Chaudhuri KR;
Eur J Neurol; 2016 Aug; 23(8):1255-61. PubMed ID: 27170229
[TBL] [Abstract][Full Text] [Related]
10. Impulse control disorders in Chinese Parkinson's disease patients: the effect of ergot derived dopamine agonist.
Auyeung M; Tsoi TH; Tang WK; Cheung CM; Lee CN; Li R; Yeung E
Parkinsonism Relat Disord; 2011 Sep; 17(8):635-7. PubMed ID: 21705258
[TBL] [Abstract][Full Text] [Related]
11. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study.
Beccuti G; Guaraldi F; Natta G; Cambria V; Prencipe N; Cicolin A; Montanaro E; Lopiano L; Ghigo E; Zibetti M; Grottoli S
J Endocrinol Invest; 2021 Aug; 44(8):1699-1706. PubMed ID: 33314003
[TBL] [Abstract][Full Text] [Related]
12. Impulse control disorders and related behaviours (ICD-RBs) in Parkinson's disease patients: Assessment using "Questionnaire for impulsive-compulsive disorders in Parkinson's disease" (QUIP).
Sharma A; Goyal V; Behari M; Srivastva A; Shukla G; Vibha D
Ann Indian Acad Neurol; 2015; 18(1):49-59. PubMed ID: 25745311
[TBL] [Abstract][Full Text] [Related]
13. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
Linazasoro G;
J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
[TBL] [Abstract][Full Text] [Related]
14. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Inzelberg R; Schechtman E; Nisipeanu P
Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
[TBL] [Abstract][Full Text] [Related]
15. Performance on the balloon analogue risk task and anticipatory response inhibition task is associated with severity of impulse control behaviours in people with Parkinson's disease.
Hall A; Weightman M; Jenkinson N; MacDonald HJ
Exp Brain Res; 2023 Apr; 241(4):1159-1172. PubMed ID: 36894682
[TBL] [Abstract][Full Text] [Related]
16. Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?
Rascol O
J Neural Transm Suppl; 1999; 55():33-45. PubMed ID: 10335491
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
Gencler OS; Oztekin N; Oztekin MF
Ideggyogy Sz; 2022 Jan; 75(1-02):39-49. PubMed ID: 35112520
[TBL] [Abstract][Full Text] [Related]
18. The complex molecular pharmacology of the dopamine D
Ferraiolo M; Hermans E
Pharmacol Ther; 2023 May; 245():108392. PubMed ID: 36958527
[TBL] [Abstract][Full Text] [Related]
19. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
[TBL] [Abstract][Full Text] [Related]
20. Association between REM sleep behaviour disorder and impulse control disorder in patients with Parkinson's disease.
Bellosta Diago E; Lopez Del Val LJ; Santos Lasaosa S; López Garcia E; Viloria Alebesque A
Neurologia; 2017 Oct; 32(8):494-499. PubMed ID: 27087472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
